BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in its NGAL product line and a focus on expanding market adoption in the U.S. [1][4][11] Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][8] - For the fiscal year 2025, total revenue was DKK 40.3 million, up 11% from DKK 36.2 million in 2024, with a 13% increase at constant exchange rates [3][8] - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% growth year-over-year [3][8] - The adjusted EBITDA loss for FY 2025 is estimated at approximately DKK 77 million, aligning with previous guidance [3][8] 2026 Financial Guidance - For 2026, BioPorto targets total revenue of DKK 48-58 million, representing a growth of 20-45% [6][9] - Total NGAL revenue is expected to grow by 20-50%, reaching DKK 33-42 million [6][9] - The adjusted EBITDA loss for 2026 is projected to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [9] Business Strategy and Market Adoption - The company is pursuing over 60 active hospitals in the U.S. by the end of 2026 as part of its "Forward" strategy [6][11] - By the end of 2025, there were 44 active hospitals using NGAL for Research Use Only (RUO), an increase of 8 from the previous year [14] - BioPorto is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [14] Future Aspirations - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [9] - Cash flow is expected to turn positive in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [9]